Prevalence of Advanced HIV Disease, Cryptococcal Antigenemia, and Suboptimal Clinical Outcomes Among Those Enrolled in Care in Vietnam

Vu Quoc Dat, Sheryl Lyss, Nguyen Thi Hoai Dung, Le Manh Hung, Sherri L Pals, Ho Thi Van Anh, Nguyen Van Kinh, Moses Bateganya, Vu Quoc Dat, Sheryl Lyss, Nguyen Thi Hoai Dung, Le Manh Hung, Sherri L Pals, Ho Thi Van Anh, Nguyen Van Kinh, Moses Bateganya

Abstract

Background: People living with advanced HIV disease are at high risk of morbidity and mortality. We assessed the prevalence of cryptococcal antigenemia (CrAg) and clinical outcomes among patients newly presenting with CD4 ≤100 cells/μL in Vietnam.

Setting: Twenty-two public HIV clinics in Vietnam.

Methods: During August 2015-March 2017, antiretroviral therapy (ART)-naïve adults presenting for care with CD4 ≤100 cells/μL were screened for CrAg. Those who consented to study enrollment were followed up for up to 12 months and assessed for clinical outcomes.

Results: Of 3504 patients with CD4 results, 1354 (38.6%) had CD4 ≤100 cells/μL, of whom 1177 (86.9%) enrolled in the study. The median age was 35 years (interquartile range 30-40); 872 (74.1%) of them were men, and 892 (75.8%) had CD4 <50 cells/μL. Thirty-six patients (3.1%) were CrAg-positive. Overall, 1151 (97.8%) including all who were CrAg-positive initiated ART. Of 881 patients (76.5%) followed up for ≥12 months, 623 (70.7%) were still alive and on ART at 12 months, 54 (6.1%) had transferred to nonstudy clinics, 86 (9.8%) were lost to follow-up, and 104 (11.8%) had died. Among all 1177 study participants, 143 (12.1%) died, most of them (123, 86.0%) before or within 6 months of enrollment. Twenty-seven patients (18.9%) died of pulmonary tuberculosis, 23 (16.1%) died of extrapulmonary tuberculosis, 8 (5.6%) died of Talaromyces marneffei infection, and 6 (4.2%) died of opioid overdose. Eight deaths (5.8%) occurred among the 36 CrAg-positive individuals.

Conclusions: Late presentation for HIV care was common. The high mortality after entry in care calls for strengthening of the management of advanced HIV disease.

Trial registration: ClinicalTrials.gov NCT02955862.

Conflict of interest statement

The authors have no conflicts of interest to disclose.

Copyright © 2021 The Author(s). Published by Wolters Kluwer Health, Inc.

Figures

FIGURE 1.
FIGURE 1.
Flow chart of patients.
FIGURE 2.
FIGURE 2.
Cumulative all-cause mortality for study participants who initiated ART by baseline CD4 count.

References

    1. Joint United Nations Programme on HIV/AIDS (UNAIDS). Ending AIDS: Progress towards the 90–90–90 Targets. Geneva, Switzerland: UNAIDS Joint United Nations Programme on HIV/AIDS; 2017.
    1. Joint United Nations Programme on HIV/AIDS (UNAIDS). UNAIDS Data 2020. Switzerland; 2020: Available at: . Accessed November 30, 2020.
    1. World Health Organization. Guidelines for Managing Advanced HIV Disease and Rapid Initiation of Antiretroviral Therapy: World Health Organization Printed in France; 2017.
    1. Pollack TM, Duong HT, Pham TT, et al. . Routine versus targeted viral load strategy among patients starting antiretroviral in Hanoi, Vietnam. J Int AIDS Soc. 2019;22:e25258.
    1. Kato M, Long NH, Duong BD, et al. . Enhancing the benefits of antiretroviral therapy in Vietnam: towards ending AIDS. Curr HIV/AIDS Rep. 2014;11:487–495.
    1. Smith RM, Nguyen TA, Ha HT, et al. . Prevalence of cryptococcal antigenemia and cost-effectiveness of a cryptococcal antigen screening program--Vietnam. PloS one 2013;8:e62213.
    1. Chiến LT, Huy VX. Causes of death in AIDS patients in tropical diseases hospital [Vietnamese]. J Pract Med. 2005;258-259:176–178.
    1. Gaudine A, Gien L, Thuan TT, et al. . Perspectives of HIV-related stigma in a community in Vietnam: a qualitative study. Int J Nurs Stud. 2010;47:38–48.
    1. Thi MD, Brickley DB, Vinh DT, et al. . A qualitative study of stigma and discrimination against people living with HIV in Ho Chi Minh City, Vietnam. AIDS Behavior. 2008;12:S63–S70.
    1. Lim T, Zelaya C, Latkin C, et al. . Individual-level socioeconomic status and community-level inequality as determinants of stigma towards persons living with HIV who inject drugs in Thai Nguyen, Vietnam. J Int AIDS Soc. 2013;16:18637.
    1. Tran DA, Shakeshaft A, Ngo AD, et al. . Determinants of antiretroviral therapy initiation and treatment outcomes for people living with HIV in Vietnam. HIV Clin Trials. 2013;14:21–33.
    1. Nguyen DB, Do NT, Shiraishi RW, et al. . Outcomes of antiretroviral therapy in Vietnam: results from a national evaluation. PLoS One. 2013;8:e55750.
    1. Gupta A, Nadkarni G, Yang WT, et al. . Early mortality in adults initiating antiretroviral therapy (ART) in low- and middle-income countries (LMIC): a systematic review and meta-analysis. PLoS One. 2011;6:e28691.
    1. Bisson GP, Ramchandani R, Miyahara S, et al. . Risk factors for early mortality on antiretroviral therapy in advanced HIV-infected adults. AIDS. 2017;31:2217–2225.
    1. Duong AT, Kato M, Bales S, et al. . Costing analysis of national HIV treatment and care program in Vietnam. J Acquired Immune Deficiency Syndromes (1999). 2014;65:e1–e7.
    1. Joint United Nations Programme on HIV/AIDS (UNAIDS) and Vietnam Administration for HIV/AIDS Control (VAAC). A Review of HIV Prevention in Vietnam 2019. 2019: Available at: . Accessed November 30, 2020.
    1. Ministry of Health. Optimizing Viet Nam's HIV Response: An Investment Case. 2014: Available at: . Accessed November 30, 2020.
    1. Ministry of Health. Report of HIV prevention activities in 2015 and prioritized tasks in 2016. In: Vietnam Administration of AIDS Control (VAAC)/BC-BYT, ed. Vol 145. Hanoi: Ministry of Health; 2016.
    1. Ministry of Health. Guidedance on Management, Care and Treatment of HIV/AIDS, Issued with Decision No.5418/QĐ-BYT Dated 1/12/2017. The Minister of Health. 2017.
    1. Ministry of Health. Guidedance on Management, Care and Treatment of HIV/AIDS, Issued with Decision No.3047/QĐ-BYT Dated 22/7/2015. The Minister of Health. Hanoi, Vietnam: Ministry of Health; 2015.
    1. World Health Organization. Rapid Advice : Diagnosis, Prevention and Management of Cryptococcal Disease in HIV-Infected Adults, Adolescents and Children: December 2011. Geneva, Switzerland: World Health Organization; 2011.
    1. May MT, Vehreschild JJ, Trickey A, et al. . Mortality according to CD4 count at start of combination antiretroviral therapy among HIV-infected patients followed for up to 15 years after start of treatment: collaborative cohort study. Clin Infect Dis. 2016;62:1571–1577.
    1. Siika A, McCabe L, Bwakura-Dangarembizi M, et al. . Late presentation with HIV in africa: phenotypes, risk, and risk stratification in the REALITY trial. Clin Infect Dis. 2018;66:S140–S146.
    1. Pongsai P, Atamasirikul K, Sungkanuparph S. The role of serum cryptococcal antigen screening for the early diagnosis of cryptococcosis in HIV-infected patients with different ranges of CD4 cell counts. J Infect. 2010;60:474–477.
    1. Micol R, Lortholary O, Sar B, et al. . Prevalence, determinants of positivity, and clinical utility of cryptococcal antigenemia in Cambodian HIV-infected patients. J Acquir Immune Defic Syndr. 2007;45:555–559.
    1. World Health Organization. Guidelines for Managing Advanced HIV Disease and Rapid Initiation of Antiretroviral Therapy. Geneva, Switzerland: 2017. Licence: CC BY-NC-SA 3.0 IGO.
    1. Cowger TL, Thai LH, Duong BD, et al. . Programmatic evaluation of an algorithm for intensified tuberculosis case finding and isoniazid preventive therapy for people living with HIV in Thailand and Vietnam. J Acquir Immune Defic Syndr. 2017;76:512–521.
    1. Zhang J, Kern-Allely S, Yu T, et al. . HIV and tuberculosis co-infection in east Asia and the pacific from 1990 to 2017: results from the global burden of disease study 2017. J Thorac Dis. 2019;11:3822–3835.
    1. Do TN, Nguyen TM, Do MH, et al. . Combining cohort analysis and monitoring of HIV early-warning indicators of drug resistance to assess antiretroviral therapy services in Vietnam. Clin Infect Dis. 2012;54suppl 4:S306–S312.
    1. Matsumoto S, Tanuma J, Mizushima D, et al. . High treatment retention rate in HIV-infected patients receiving antiretroviral therapy at two large HIV clinics in Hanoi, Vietnam. PLoS One. 2015;10:e0139594.
    1. Fox MP, Rosen S. Retention of adult patients on antiretroviral therapy in low- and middle-income countries: systematic review and meta-analysis 2008-2013. J Acquir Immune Defic Syndr. 2015;69:98–108.
    1. World Health Organization. Guidelines for Managing Advanced HIV Disease and Rapid Initiation of Antiretroviral Therapy. Geneva, Switzerland: World Health Organization; 2017.
    1. Cuong do D, Thorson A, Sonnerborg A, et al. . Survival and causes of death among HIV-infected patients starting antiretroviral therapy in north-eastern Vietnam. Scand J Infect Dis. 2012;44:201–208.
    1. Faini D, Kalinjuma AV, Katende A, et al. . Laboratory-reflex cryptococcal antigen screening is associated with a survival benefit in Tanzania. J Acquir Immune Defic Syndr. 2019;80:205–213.
    1. Buchacz K, Lau B, Jing Y, et al. . Incidence of AIDS-defining opportunistic infections in a multicohort analysis of HIV-infected persons in the United States and Canada, 2000-2010. J Infect Dis. 2016;214:862–872.
    1. Chammartin F, Zurcher K, Keiser O, et al. . Outcomes of patients lost to follow-up in african antiretroviral therapy programs: individual patient data meta-analysis. Clin Infect Dis. 2018;67:1643–1652.
    1. World Health Organization. Package of Care for Children and Adolescents with Advanced HIV Disease: Stop AIDS: Technical Brief. Geneva, Switzerland: World Health Organization; 2020.

Source: PubMed

Sponsorer og samarbeidspartnere

Medisinsk tilstand

Legemiddelintervensjoner

3
Abonnere